Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage...
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial...
View ArticleJeito Capital demonstrates European biopharma leadership with first exit with...
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by world-leading teams in therapeutic areas with high unmet need Paris, France, November 29th 2022 – Jeito...
View ArticleJeito Capital strengthens its support in Pulmocide with participation in $52...
The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole. Paris, France,...
View ArticleJeito Capital co-leads a EUR 104 million financing in Noema Pharma, a...
Noema Pharma’s clinical-stage assets and diversified pipeline hold significant potential in developing effective therapeutic options for patients with debilitating central nervous system (CNS)...
View ArticleJeito Capital leads a $105 million Series C financing in Alentis Therapeutics...
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development...
View ArticleJeito Capital co-leads EUR 65 million (USD 71 million) financing in Corteria...
Jeito Capital co-leads oversubscribed financing Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure...
View ArticleJeito Capital renewed in “TIBI 2”
Paris, France, September 11th 2023 – Three years after being the 1st biopharma fund to be awarded the Tibi 1 label, Jeito Capital has announced that it has been renewed in the Tibi 2 selection,...
View ArticleEyeBio Announces Expansion of Series A to $130 Million, Advances Development...
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support...
View ArticleJeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish...
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global, clinical-stage company, with a strong pipeline of breakthrough therapies for patients suffering from...
View ArticleJeito Capital creates a community of leading international Special Advisors...
Paris, France, November 29th 2023 – Jeito Capital (“Jeito”), a leading global investment company dedicated to biopharmaceuticals in Europe, is proud to announce the formation of its Special Advisors...
View Article